{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:07:38Z","timestamp":1771355258886,"version":"3.50.1"},"reference-count":62,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Invasive pulmonary aspergillosis (IPA) is a devastating disease of immunocompromised patients. Pharmacodynamic (PD) examination of antifungal drug therapy in IPA is one strategy that may improve outcomes. The current study explored the PD target of posaconazole in an immunocompromised murine model of IPA against 10\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">A. fumigatus<\/jats:named-content>\n            isolates, including 4\n            <jats:italic>Cyp51<\/jats:italic>\n            wild-type isolates and 6 isolates carrying\n            <jats:italic>Cyp51<\/jats:italic>\n            mutations conferring azole resistance. The posaconazole MIC range was 0.25 to 8 mg\/liter. Following infection, mice were given 0.156 to 160 mg\/kg of body weight of oral posaconazole daily for 7 days. Efficacy was assessed by quantitative PCR (qPCR) of lung homogenate and survival. At the start of therapy, mice had 5.59 \u00b1 0.19 log\n            <jats:sub>10<\/jats:sub>\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus<\/jats:named-content>\n            conidial equivalents (CE)\/ml of lung homogenate, which increased to 7.11 \u00b1 0.29 log\n            <jats:sub>10<\/jats:sub>\n            CE\/ml of lung homogenate in untreated animals. The infection was uniformly lethal prior to the study endpoint in control mice. A Hill-type dose response function was used to model the relationship between posaconazole free drug area under the concentration-time curve (AUC)\/MIC and qPCR lung burden. The static dose range was 1.09 to 51.9 mg\/kg\/24 h. The free drug AUC\/MIC PD target was 1.09 \u00b1 0.63 for the group of strains. The 1-log kill free drug AUC\/MIC was 2.07 \u00b1 1.02. The PD target was not significantly different for the wild-type and mutant organism groups. Mortality mirrored qPCR results, with the greatest improvement in survival noted at the same dosing regimens that produced static or cidal activity. Consideration of human pharmacokinetic data and the current static dose PD target would predict a clinical MIC threshold of 0.25 to 0.5 mg\/liter.\n          <\/jats:p>","DOI":"10.1128\/aac.01279-12","type":"journal-article","created":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T12:24:10Z","timestamp":1352809450000},"page":"579-585","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":63,"title":["Posaconazole Pharmacodynamic Target Determination against Wild-Type and\n            <i>Cyp51<\/i>\n            Mutant Isolates of Aspergillus fumigatus in an\n            <i>In Vivo<\/i>\n            Model of Invasive Pulmonary Aspergillosis"],"prefix":"10.1128","volume":"57","author":[{"given":"Alexander J.","family":"Lepak","sequence":"first","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Marchillo","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimie","family":"VanHecker","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Andes","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/651262"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2006.06.007"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.4.539"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.780-782.2000"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006970503053"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1124"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1504"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.857-869.2001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/508774"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00705-08"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05900-11"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31823cdeac"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780400029130"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.508469"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050219"},{"key":"e_1_3_2_24_2","volume-title":"CLSI document M38-A2.","author":"Clinical Laboratory Standards Institute","year":"2007","unstructured":"Clinical Laboratory Standards Institute. 2007. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2375"},{"key":"e_1_3_2_26_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother","author":"Lepak A","year":"2010","unstructured":"LepakA SanchezH MarchilloK AndesD. 2010. Comparative pharmacodynamics of a triazole and echinocandin for invasive pulmonary aspergillosis. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC. http:\/\/www.icaac.org\/."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr142"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00715-08"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.469-473.2006"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3474-3481.2001"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00276-08"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.25.5.931-932.1987"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02073-08"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir023"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-09"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.505204"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/652768"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1295715"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/510592"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1193-1199.2003"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2116"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00116-08"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3171-3177.2005"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1392"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2715-2718.2000"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1105"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00606-10"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-06"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1086\/524669"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-07"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1570-1572.2006"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1128-2"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802213340"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780400029429"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.08.001"},{"key":"e_1_3_2_60_2","first-page":"87","article-title":"Newer animal models of Aspergillus and Candida infections","volume":"1","author":"Steinbach WJ","year":"2004","unstructured":"SteinbachWJ ZaasAK. 2004. Newer animal models of Aspergillus and Candida infections. Drug Discov. Today 1:87\u201393.","journal-title":"Drug Discov. Today"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.12.3935-3941.2003"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1665-1670.2002"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2788-2795.2003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01279-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01279-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:29:53Z","timestamp":1645482593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01279-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1128\/AAC.01279-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01279-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"2012-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}